bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Title: Intranasal type I interferon treatment is beneficial only when
administered before clinical signs onset in the SARS-CoV-2 hamster model
Authors: Pierre Bessière1, Marine Wasniewski2†, Evelyne Picard-Meyer2†, Alexandre Servat2†,
Thomas Figueroa1, Charlotte Foret-Lucas1, Amelia Coggon1, Sandrine Lesellier3, Frank Boué2,
Nathan Cebron1, Blandine Gausserès1, Catherine Trumel4, Gilles Foucras1, Francisco J
Salguero5, Elodie Monchatre-Leroy2 and Romain Volmer1*

5

Affiliations:
1

10

Ecole nationale vétérinaire de Toulouse, ENVT, INRAE, UMR 1225, IHAP, Université de
Toulouse, Toulouse, France.
2

Nancy laboratory for rabies and wildlife, ANSES, Lyssavirus Unit, Malzéville, France

3

Nancy laboratory for rabies and wildlife, ANSES, Atton experimental facility, Atton, France

4

Ecole nationale vétérinaire de Toulouse, ENVT, CREFRE, INSERM, Université de Toulouse,
Toulouse, France
15

5

National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire,
SP4 0JG, UK.

*Correspondence to: romain.volmer@envt.fr
† equal contribution
20

25

1

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Abstract:

5

Impaired type I interferons (IFNs) production or signaling have been associated with severe
COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against
SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of
IFN-α starting one day pre-infection or one day post-infection limited weight loss and decreased
viral lung titers. By contrast, intranasal administration of IFN-α starting at the onset of symptoms
three days post-infection had no impact on the clinical course of SARS-CoV-2 infection. Our
results provide evidence that early type I IFN treatments are beneficial, while late interventions
are ineffective, although not associated with signs of enhanced disease.

10

One Sentence Summary:
The timing of type I interferon treatment is a critical determinant of its efficacy against SARSCoV-2 infection.
15

20

25

30

35

40

Main Text:
Type I interferons (IFNs) are major antiviral cytokines and their finely tuned production is
critical for host protection against viruses (1). In vitro studies demonstrated that SARS-CoV-2
was very sensitive to the antiviral effects of type I IFN (2–4). In addition, development of severe
COVID-19 was shown to correlate with decreased type I IFNs production or impaired type I IFN
signaling (5–9). In agreement with these observations, recombinant type I IFNs are being tested
in a number of clinical trials to treat COVID-19 patients (10–12). However, the design and
interpretation of these clinical trials need to consider that the timing of type I IFN treatment may
be critical for its efficacy and safety against SARS-CoV-2 (13, 14). Indeed, studies in SARSCoV and MERS-CoV infected mice demonstrated that type I IFN-treatment was beneficial when
administered early, while it was deleterious when administered at later stages of infection (15,
16). How the timing of type I IFN treatments modulate their clinical efficacy against SARSCoV-2 is currently unknown and needs to be tested in an animal model.
To address this question, we designed a study that evaluated the prophylactic and therapeutic
efficacy of intranasally administered recombinant universal IFN-α (rIFN) against SARS-CoV-2
infection in Syrian hamsters (Fig. 1A). Hamsters intranasally infected with a high dose SARSCoV-2 develop clinical disease caused by lung pathology, which closely mirrors severe human
COVID-19 (17, 18). In a preliminary experiment, we observed a significant upregulation of the
expression of the type I IFN stimulated gene (ISG) Mx2 in the nasal turbinates, lung and spleen
of hamsters treated intranasally with rIFN, demonstrating that this molecule was active in
hamsters (Fig. S1). Following challenge with 104 TCID50 of SARS-CoV-2, no protection from
weight loss was observed in the IFN-late group, for which treatment was initiated at the onset of
clinical signs, when infected animals started to significantly lose weight three days post-infection
(Fig. 1B). By contrast, we observed a significant protection from weight loss in the IFN-pre
group (prophylactic treatment initiated 16 hours before infection) and in the IFN-early group
(treatment initiated at one day post-infection) compared to the placebo group (Fig. 1B). The
protection from weight loss in the IFN-pre and in the IFN-early groups was not associated with a
reduction of viral excretion level or duration, as viral RNA levels measured by RT-qPCR from
oropharyngeal swabs were similar in all groups (Fig. 1C). In agreement with this observation,
2

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

5

10

15

20

25

30

35

40

45

subgenomic viral RNA levels in the nasal turbinates were similar in all groups (Fig. S2). As
SARS-CoV-2 respiratory disease is due to lower respiratory tract damage, we analyzed viral load
in the lungs. We detected a reduction of pulmonary viral subgenomic RNA levels and infectious
viral titers in all the IFN-treated groups at day 5 post-infection, compared to the placebo group,
which reached statistical significance in the IFN-early group only (Fig. 1 D&E).
Evaluation of the respiratory tract from infected animals revealed a mild to moderate
bronchointerstitial pneumonia at day 2 post-infection, progressing to moderate/severe with lung
consolidation at day 5 and resolving at day 15 with only small lesioned areas remaining, as
previously observed (18). The lesions were characterized by infiltrates of macrophages and
neutrophils, with fewer lymphocytes and plasma cells (Fig. 2A & Fig. S3). A reduction of the
lung pathology scores was observed in the IFN-treated groups compared to the placebo group
(Fig. 2B). RNAScope in situ hybridization (ISH) was used to determine the localization of viral
RNA in the lungs of infected animals. Viral RNA was observed in bronchial and bronchiolar
epithelial cells and in regions of inflammatory infiltrates at day 2 post-infection (Fig. S3). The
viral RNA positive area diminished at day 5 and coincided with inflammatory infiltrates.
Quantification of viral RNA positive area revealed a slight non-statistically significant reduction
of viral RNA in the IFN-pre and in the IFN-early groups at day 2 and 5 post-infection compared
to the placebo group (Fig. 2C). Mx1 is an ISG and its level of expression is a good indicator of
the levels of type I and type III IFN produced locally (19). Mx1 protein was upregulated in the
lungs of infected hamsters, as detected by immunohistochemistry, and the percentage of Mx1
positive lung was equivalent in placebo and IFN-treated hamsters (Fig. 2D & Fig. S3). Finally,
hematological analyses revealed a modest lymphocytopenia in SARS-CoV-2 infected hamsters,
with no difference between the IFN-treated groups and the placebo group (Fig. S4).
To explore the consequences of type I IFN administration on the immune response to SARSCoV-2 infection, we analyzed the expression of immune markers gene expression from the lungs
of animals euthanized at day 2 and 5 post-infection. Compared to the non-infected animals, all
the infected groups presented a significant upregulation of the ISGs Mx2 and ISG15 and of the
C–X–C motif chemokine ligand 10 (CXCL10) messenger RNA (mRNA) expression at day 2 and
5 post-infection, with no difference between the placebo and the IFN-treated groups (Fig. 3A).
The mRNA expression levels of IFN-γ, and the interleukins (ILs) IL-10 and IL-6 were also
significantly upregulated in the infected animals at day 5 post-infection. Similar results were
obtained for other immune markers analyzed by RT-qPCR in the lung (Fig. S5), nasal turbinates
(Fig. S6) and spleen (Fig. S7). We also measured the protein levels of chemokine and cytokines
either in the lungs or plasma using a commercial enzyme-linked immunosorbent assay (ELISA)
directed against hamster IL-6 or a custom-developed hamster multiplex assay. Compared to noninfected animals, we detected an upregulation of CXCL10 and IL-10 protein levels in the lung of
all infected groups, with no difference between the placebo and the IFN-treated groups (Fig. 3B).
We detected a reduction of lung IL-1β levels in IFN-treated groups compared to placebo.
Interestingly, lung IL-6 protein level and plasmatic chemokine ligand 2 (CCL2) and tumor
necrosis factor-α (TNF-α) protein levels were upregulated in the IFN-late group, compared to the
IFN-pre and IFN-early group (Fig. 3B&C).
In this study, we assessed the in vivo prophylactic and therapeutic efficacy of type I IFN
treatment against SARS-CoV-2 infection in the hamster model. Our study demonstrates that type
I IFN treatment is beneficial when administered prophylactically or one day post-infection,
confirming recent observations in hamsters (20). Similar findings were obtained when mice were
3

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

5

10

15

20

25

30

35

40

treated prophylactically or at 12 hours post-infection with type III interferon or with the synthetic
viral RNA analog poly(I:C) (21, 22). Altogether, these studies demonstrate that stimulation of
the antiviral innate immune response before infection or at the very early phase of infection
inhibits SARS-CoV-2 replication and pathogenesis, as expected given the high level of SARSCoV-2 sensitivity to prophylactic type I and type III IFN treatment observed in cell culture (2–4).
By contrasts, administration of type I IFN as soon as the animals exhibited the first clinical signs,
corresponding to weight loss, three days post-infection, was not associated with any change in
clinical signs compared to placebo treated hamsters. Therefore, this study does not support the
use of intranasal type I IFN as a therapeutic in patients with COVID-19 symptoms.
In comparison to humans, virus replication and lung pathology progress much faster in hamsters,
which have a peak of virus replication in the lungs at day 2-3 and a peak in clinical signs at day
6-7 (17). Treatment at day 3 post-infection thus corresponds to a “late” time point for treatment
initiation in hamsters. We detected an upregulation of IL-6, CCL2 and TNF-α protein levels in
the IFN-late group, compared to the IFN-pre and IFN-early groups. However, this did not result
in enhanced pathology compared to the placebo group. Our results therefore indicate that type I
IFN treatments at late time-points are unlikely to be associated with deleterious
immunopathology exacerbation mechanisms, which were observed in SARS-CoV-1 and MERS
virus infected mice and feared in SARS-CoV-2-infected humans (13, 15, 16). A contribution of
type I IFNs to SARS-CoV-2 lung pathology has been suggested from work in IFNAR knockout
mice transduced with adenovirus expressing human ACE2 and in STAT2 knockout hamsters
(21, 23, 24). However, heightened viral loads were also observed in IFNAR knockout mice and
STAT2 knockout hamsters, illustrating the fact that type I IFNs can have beneficial and
deleterious effects most likely depending on the stage of SARS-CoV-2 infection (21, 24). SARSCoV-2 expresses a broad array of type I IFN signaling antagonists that likely account for the low
sensitivity observed in post-infection type I IFN treatments in cell culture (Fig. S8), and for the
lack of beneficial effects observed in this study when type I IFN treatment was initiated at the
onset of symptoms three days post-infection (4, 25, 26).
Even though SARS-CoV-2 expresses a broad array of type I IFN signaling antagonists, we
detected a significant upregulation of ISGs expression in the respiratory tract of SARS-CoV-2
infected hamsters, similarly to what has been described in COVID-19 patients (27). Interestingly,
ISGs expression in the respiratory tract was not further increased by IFN treatments, as
previously observed in MERS-CoV infected mice treated with IFN-beta at 2 days post-infection
(16). This result suggests that ISGs levels had reached their maximal in response to virusinduced endogenous type I and type III IFNs production and could not be further augmented
following exogenous type I IFN administration.
Our study demonstrates that the timing of the type I IFN treatment is critical for its efficacy in a
preclinical model of severe SARS-CoV-2 infection. Results from the SOLIDARITY clinical trial
showed no benefit of subcutaneous interferon-β-1a injection, while a phase-two clinical trial
provided evidence of some benefits of inhaled interferon-β-1a in COVID-19 patients (12, 28).
The route of type I IFN administration was not the sole difference between these trials, as the
patients treated in the SOLIDARITY trial were on average at a more severe stage of the disease.
Our findings support the hypothesis that type I IFN treatments may only be beneficial in patients
with mild symptoms at the early stages of the disease, while they are likely to provide no benefit
in COVID-19 patients requiring hospitalization (29).

4

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

References and Notes:

5

10

1.

F. McNab, K. Mayer-Barber, A. Sher, A. Wack, A. O’Garra, Type I interferons in
infectious disease. Nature Reviews Immunology. 15, 87–103 (2015).

2.

K. G. Lokugamage, A. Hage, M. de Vries, A. M. Valero-Jimenez, C. Schindewolf, M.
Dittmann, R. Rajsbaum, V. D. Menachery, Type I Interferon Susceptibility Distinguishes
SARS-CoV-2 from SARS-CoV. J Virol. 94 (2020), doi:10.1128/JVI.01410-20.

3.

E. Mantlo, N. Bukreyeva, J. Maruyama, S. Paessler, C. Huang, Antiviral activities of type I
interferons to SARS-CoV-2 infection. Antiviral Res. 179, 104811 (2020).

4.

L. Miorin, T. Kehrer, M. T. Sanchez-Aparicio, K. Zhang, P. Cohen, R. S. Patel, A. Cupic,
T. Makio, M. Mei, E. Moreno, O. Danziger, K. M. White, R. Rathnasinghe, M. Uccellini,
S. Gao, T. Aydillo, I. Mena, X. Yin, L. Martin-Sancho, N. J. Krogan, S. K. Chanda, M.
Schotsaert, R. W. Wozniak, Y. Ren, B. R. Rosenberg, B. M. A. Fontoura, A. García-Sastre,
SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon
signaling. PNAS. 117, 28344–28354 (2020).

5.

J. Hadjadj, N. Yatim, L. Barnabei, A. Corneau, J. Boussier, N. Smith, H. Péré, B. Charbit,
V. Bondet, C. Chenevier-Gobeaux, P. Breillat, N. Carlier, R. Gauzit, C. Morbieu, F. Pène,
N. Marin, N. Roche, T.-A. Szwebel, S. H. Merkling, J.-M. Treluyer, D. Veyer, L. Mouthon,
C. Blanc, P.-L. Tharaux, F. Rozenberg, A. Fischer, D. Duffy, F. Rieux-Laucat, S. Kernéis,
B. Terrier, Impaired type I interferon activity and inflammatory responses in severe
COVID-19 patients. Science. 369, 718–724 (2020).

6.

P. Bastard, L. B. Rosen, Q. Zhang, E. Michailidis, H.-H. Hoffmann, Y. Zhang, K.
Dorgham, Q. Philippot, J. Rosain, V. Béziat, J. Manry, E. Shaw, L. Haljasmägi, P.
Peterson, L. Lorenzo, L. Bizien, S. Trouillet-Assant, K. Dobbs, A. A. de Jesus, A. Belot, A.
Kallaste, E. Catherinot, Y. Tandjaoui-Lambiotte, J. Le Pen, G. Kerner, B. Bigio, Y.
Seeleuthner, R. Yang, A. Bolze, A. N. Spaan, O. M. Delmonte, M. S. Abers, A. Aiuti, G.
Casari, V. Lampasona, L. Piemonti, F. Ciceri, K. Bilguvar, R. P. Lifton, M. Vasse, D. M.
Smadja, M. Migaud, J. Hadjadj, B. Terrier, D. Duffy, L. Quintana-Murci, D. van de Beek,
L. Roussel, D. C. Vinh, S. G. Tangye, F. Haerynck, D. Dalmau, J. Martinez-Picado, P.
Brodin, M. C. Nussenzweig, S. Boisson-Dupuis, C. Rodríguez-Gallego, G. Vogt, T. H.
Mogensen, A. J. Oler, J. Gu, P. D. Burbelo, J. I. Cohen, A. Biondi, L. R. Bettini, M.
D’Angio, P. Bonfanti, P. Rossignol, J. Mayaux, F. Rieux-Laucat, E. S. Husebye, F. Fusco,
M. V. Ursini, L. Imberti, A. Sottini, S. Paghera, E. Quiros-Roldan, C. Rossi, R. Castagnoli,
D. Montagna, A. Licari, G. L. Marseglia, X. Duval, J. Ghosn, HGID Lab, NIAID-USUHS
Immune Response to COVID Group, COVID Clinicians, COVID-STORM Clinicians,
Imagine COVID Group, French COVID Cohort Study Group, Milieu Intérieur Consortium,
CoV-Contact Cohort, Amsterdam UMC Covid-19 Biobank, COVID Human Genetic Effort,
J. S. Tsang, R. Goldbach-Mansky, K. Kisand, M. S. Lionakis, A. Puel, S.-Y. Zhang, S. M.
Holland, G. Gorochov, E. Jouanguy, C. M. Rice, A. Cobat, L. D. Notarangelo, L. Abel, H.
C. Su, J.-L. Casanova, Autoantibodies against type I IFNs in patients with life-threatening
COVID-19. Science. 370 (2020), doi:10.1126/science.abd4585.

15

20

25

30

35

40

5

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

7.

Q. Zhang, P. Bastard, Z. Liu, J. Le Pen, M. Moncada-Velez, J. Chen, M. Ogishi, I. K. D.
Sabli, S. Hodeib, C. Korol, J. Rosain, K. Bilguvar, J. Ye, A. Bolze, B. Bigio, R. Yang, A.
A. Arias, Q. Zhou, Y. Zhang, F. Onodi, S. Korniotis, L. Karpf, Q. Philippot, M. Chbihi, L.
Bonnet-Madin, K. Dorgham, N. Smith, W. M. Schneider, B. S. Razooky, H.-H. Hoffmann,
E. Michailidis, L. Moens, J. E. Han, L. Lorenzo, L. Bizien, P. Meade, A.-L. Neehus, A. C.
Ugurbil, A. Corneau, G. Kerner, P. Zhang, F. Rapaport, Y. Seeleuthner, J. Manry, C.
Masson, Y. Schmitt, A. Schlüter, T. Le Voyer, T. Khan, J. Li, J. Fellay, L. Roussel, M.
Shahrooei, M. F. Alosaimi, D. Mansouri, H. Al-Saud, F. Al-Mulla, F. Almourfi, S. Z. AlMuhsen, F. Alsohime, S. Al Turki, R. Hasanato, D. van de Beek, A. Biondi, L. R. Bettini,
M. D’Angio’, P. Bonfanti, L. Imberti, A. Sottini, S. Paghera, E. Quiros-Roldan, C. Rossi,
A. J. Oler, M. F. Tompkins, C. Alba, I. Vandernoot, J.-C. Goffard, G. Smits, I. Migeotte, F.
Haerynck, P. Soler-Palacin, A. Martin-Nalda, R. Colobran, P.-E. Morange, S. Keles, F.
Çölkesen, T. Ozcelik, K. K. Yasar, S. Senoglu, Ş. N. Karabela, C. Rodríguez-Gallego, G.
Novelli, S. Hraiech, Y. Tandjaoui-Lambiotte, X. Duval, C. Laouénan, COVID-STORM
Clinicians, COVID Clinicians, Imagine COVID Group, French COVID Cohort Study
Group, CoV-Contact Cohort, Amsterdam UMC Covid-19 Biobank, COVID Human
Genetic Effort, NIAID-USUHS/TAGC COVID Immunity Group, A. L. Snow, C. L.
Dalgard, J. D. Milner, D. C. Vinh, T. H. Mogensen, N. Marr, A. N. Spaan, B. Boisson, S.
Boisson-Dupuis, J. Bustamante, A. Puel, M. J. Ciancanelli, I. Meyts, T. Maniatis, V.
Soumelis, A. Amara, M. Nussenzweig, A. García-Sastre, F. Krammer, A. Pujol, D. Duffy,
R. P. Lifton, S.-Y. Zhang, G. Gorochov, V. Béziat, E. Jouanguy, V. Sancho-Shimizu, C. M.
Rice, L. Abel, L. D. Notarangelo, A. Cobat, H. C. Su, J.-L. Casanova, Inborn errors of type
I IFN immunity in patients with life-threatening COVID-19. Science. 370 (2020),
doi:10.1126/science.abd4570.

25

8.

I.-E. Galani, N. Rovina, V. Lampropoulou, V. Triantafyllia, M. Manioudaki, E. Pavlos, E.
Koukaki, P. C. Fragkou, V. Panou, V. Rapti, O. Koltsida, A. Mentis, N. Koulouris, S.
Tsiodras, A. Koutsoukou, E. Andreakos, Untuned antiviral immunity in COVID-19
revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol. 22,
32–40 (2021).

30

9.

E. Pairo-Castineira, S. Clohisey, L. Klaric, A. D. Bretherick, K. Rawlik, D. Pasko, S.
Walker, N. Parkinson, M. H. Fourman, C. D. Russell, J. Furniss, A. Richmond, E.
Gountouna, N. Wrobel, D. Harrison, B. Wang, Y. Wu, A. Meynert, F. Griffiths, W.
Oosthuyzen, A. Kousathanas, L. Moutsianas, Z. Yang, R. Zhai, C. Zheng, G. Grimes, R.
Beale, J. Millar, B. Shih, S. Keating, M. Zechner, C. Haley, D. J. Porteous, C. Hayward, J.
Yang, J. Knight, C. Summers, M. Shankar-Hari, P. Klenerman, L. Turtle, A. Ho, S. C.
Moore, C. Hinds, P. Horby, A. Nichol, D. Maslove, L. Ling, D. McAuley, H. Montgomery,
T. Walsh, A. Pereira, A. Renieri, X. Shen, C. P. Ponting, A. Fawkes, A. Tenesa, M.
Caulfield, R. Scott, K. Rowan, L. Murphy, P. J. M. Openshaw, Malcolm G. Semple, A.
Law, V. Vitart, J. F. Wilson, J. K. Baillie, Genetic mechanisms of critical illness in Covid19. Nature, 1–1 (2020).

5

10

15

20

35

40

10. E. Sallard, F.-X. Lescure, Y. Yazdanpanah, F. Mentre, N. Peiffer-Smadja, Type 1
interferons as a potential treatment against COVID-19. Antiviral Res. 178, 104791 (2020).

6

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

11. G. Schreiber, The Role of Type I Interferons in the Pathogenesis and Treatment of COVID19. Front. Immunol. 11 (2020), doi:10.3389/fimmu.2020.595739.

5

10

15

12. P. D. Monk, R. J. Marsden, V. J. Tear, J. Brookes, T. N. Batten, M. Mankowski, F. J.
Gabbay, D. E. Davies, S. T. Holgate, L.-P. Ho, T. Clark, R. Djukanovic, T. M. A.
Wilkinson, Inhaled Interferon Beta COVID-19 Study Group, Safety and efficacy of inhaled
nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a
randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med (2020),
doi:10.1016/S2213-2600(20)30511-7.
13. A. Park, A. Iwasaki, Type I and Type III Interferons – Induction, Signaling, Evasion, and
Application to Combat COVID-19. Cell Host & Microbe (2020),
doi:10.1016/j.chom.2020.05.008.
14. N. Wang, Y. Zhan, L. Zhu, Z. Hou, F. Liu, P. Song, F. Qiu, X. Wang, X. Zou, D. Wan, X.
Qian, S. Wang, Y. Guo, H. Yu, M. Cui, G. Tong, Y. Xu, Z. Zheng, Y. Lu, P. Hong,
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with
Favorable Clinical Responses in COVID-19 Patients. Cell Host & Microbe. 28, 455-464.e2
(2020).
15. R. Channappanavar, A. R. Fehr, R. Vijay, M. Mack, J. Zhao, D. K. Meyerholz, S. Perlman,
Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause
Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 19, 181–193 (2016).

20

25

30

35

40

16. R. Channappanavar, A. R. Fehr, J. Zheng, C. Wohlford-Lenane, J. E. Abrahante, M. Mack,
R. Sompallae, P. B. McCray, D. K. Meyerholz, S. Perlman, IFN-I response timing relative
to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 129,
3625–3639 (2019).
17. C. Muñoz-Fontela, W. E. Dowling, S. G. P. Funnell, P.-S. Gsell, A. X. Riveros-Balta, R. A.
Albrecht, H. Andersen, R. S. Baric, M. W. Carroll, M. Cavaleri, C. Qin, I. Crozier, K.
Dallmeier, L. de Waal, E. de Wit, L. Delang, E. Dohm, W. P. Duprex, D. Falzarano, C. L.
Finch, M. B. Frieman, B. S. Graham, L. E. Gralinski, K. Guilfoyle, B. L. Haagmans, G. A.
Hamilton, A. L. Hartman, S. Herfst, S. J. F. Kaptein, W. B. Klimstra, I. Knezevic, P. R.
Krause, J. H. Kuhn, R. Le Grand, M. G. Lewis, W.-C. Liu, P. Maisonnasse, A. K. McElroy,
V. Munster, N. Oreshkova, A. L. Rasmussen, J. Rocha-Pereira, B. Rockx, E. Rodríguez, T.
F. Rogers, F. J. Salguero, M. Schotsaert, K. J. Stittelaar, H. J. Thibaut, C.-T. Tseng, J.
Vergara-Alert, M. Beer, T. Brasel, J. F. W. Chan, A. García-Sastre, J. Neyts, S. Perlman, D.
S. Reed, J. A. Richt, C. J. Roy, J. Segalés, S. S. Vasan, A. M. Henao-Restrepo, D. H.
Barouch, Animal models for COVID-19. Nature, 1–7 (2020).
18. L. H. Tostanoski, F. Wegmann, A. J. Martinot, C. Loos, K. McMahan, N. B. Mercado, J.
Yu, C. N. Chan, S. Bondoc, C. E. Starke, M. Nekorchuk, K. Busman-Sahay, C. PiedraMora, L. M. Wrijil, S. Ducat, J. Custers, C. Atyeo, S. Fischinger, J. S. Burke, J. Feldman,
B. M. Hauser, T. M. Caradonna, E. A. Bondzie, G. Dagotto, M. S. Gebre, C. Jacob-Dolan,
Z. Lin, S. H. Mahrokhian, F. Nampanya, R. Nityanandam, L. Pessaint, M. Porto, V. Ali, D.
Benetiene, K. Tevi, H. Andersen, M. G. Lewis, A. G. Schmidt, D. A. Lauffenburger, G.
7

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Alter, J. D. Estes, H. Schuitemaker, R. Zahn, D. H. Barouch, Ad26 vaccine protects against
SARS-CoV-2 severe clinical disease in hamsters. Nat Med. 26, 1694–1700 (2020).

5

10

15

20

25

30

35

19. D. Holzinger, C. Jorns, S. Stertz, S. Boisson-Dupuis, R. Thimme, M. Weidmann, J.-L.
Casanova, O. Haller, G. Kochs, Induction of MxA Gene Expression by Influenza A Virus
Requires Type I or Type III Interferon Signaling. Journal of Virology. 81, 7776–7785
(2007).
20. D. A. Hoagland, R. Møller, S. A. Uhl, K. Oishi, J. Frere, I. Golynker, S. Horiuchi, M. Panis,
D. Blanco-Melo, D. Sachs, K. Arkun, J. K. Lim, B. R. tenOever, Leveraging the antiviral
type-I interferon system as a first line defense against SARS-CoV-2 pathogenicity.
Immunity (2021), doi:10.1016/j.immuni.2021.01.017.
21. J. Sun, Z. Zhuang, J. Zheng, K. Li, R. L.-Y. Wong, D. Liu, J. Huang, J. He, A. Zhu, J.
Zhao, X. Li, Y. Xi, R. Chen, A. N. Alshukairi, Z. Chen, Z. Zhang, C. Chen, X. Huang, F.
Li, X. Lai, D. Chen, L. Wen, J. Zhuo, Y. Zhang, Y. Wang, S. Huang, J. Dai, Y. Shi, K.
Zheng, M. R. Leidinger, J. Chen, Y. Li, N. Zhong, D. K. Meyerholz, P. B. McCray, S.
Perlman, J. Zhao, Generation of a Broadly Useful Model for COVID-19 Pathogenesis,
Vaccination, and Treatment. Cell. 182, 734-743.e5 (2020).
22. K. H. Dinnon, S. R. Leist, A. Schäfer, C. E. Edwards, D. R. Martinez, S. A. Montgomery,
A. West, B. L. Yount, Y. J. Hou, L. E. Adams, K. L. Gully, A. J. Brown, E. Huang, M. D.
Bryant, I. C. Choong, J. S. Glenn, L. E. Gralinski, T. P. Sheahan, R. S. Baric, A mouseadapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 586, 560–566
(2020).
23. B. Israelow, E. Song, T. Mao, P. Lu, A. Meir, F. Liu, M. M. Alfajaro, J. Wei, H. Dong, R. J.
Homer, A. Ring, C. B. Wilen, A. Iwasaki, Mouse model of SARS-CoV-2 reveals
inflammatory role of type I interferon signaling. Journal of Experimental Medicine. 217
(2020), doi:10.1084/jem.20201241.
24. R. Boudewijns, H. J. Thibaut, S. J. F. Kaptein, R. Li, V. Vergote, L. Seldeslachts, J. Van
Weyenbergh, C. De Keyzer, L. Bervoets, S. Sharma, L. Liesenborghs, J. Ma, S. Jansen, D.
Van Looveren, T. Vercruysse, X. Wang, D. Jochmans, E. Martens, K. Roose, D. De
Vlieger, B. Schepens, T. Van Buyten, S. Jacobs, Y. Liu, J. Martí-Carreras, B.
Vanmechelen, T. Wawina-Bokalanga, L. Delang, J. Rocha-Pereira, L. Coelmont, W. Chiu,
P. Leyssen, E. Heylen, D. Schols, L. Wang, L. Close, J. Matthijnssens, M. Van Ranst, V.
Compernolle, G. Schramm, K. Van Laere, X. Saelens, N. Callewaert, G. Opdenakker, P.
Maes, B. Weynand, C. Cawthorne, G. Vande Velde, Z. Wang, J. Neyts, K. Dallmeier,
STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2
infected hamsters. Nature Communications. 11, 5838 (2020).
25. X. Lei, X. Dong, R. Ma, W. Wang, X. Xiao, Z. Tian, C. Wang, Y. Wang, L. Li, L. Ren, F.
Guo, Z. Zhao, Z. Zhou, Z. Xiang, J. Wang, Activation and evasion of type I interferon
responses by SARS-CoV-2. Nature Communications. 11, 3810 (2020).

40

26. H. Xia, Z. Cao, X. Xie, X. Zhang, J. Y.-C. Chen, H. Wang, V. D. Menachery, R. Rajsbaum,
P.-Y. Shi, Evasion of Type I Interferon by SARS-CoV-2. Cell Reports. 33, 108234 (2020).
8

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

27. Z. Zhou, L. Ren, L. Zhang, J. Zhong, Y. Xiao, Z. Jia, L. Guo, J. Yang, C. Wang, S. Jiang,
D. Yang, G. Zhang, H. Li, F. Chen, Y. Xu, M. Chen, Z. Gao, J. Yang, J. Dong, B. Liu, X.
Zhang, W. Wang, K. He, Q. Jin, M. Li, J. Wang, Heightened Innate Immune Responses in
the Respiratory Tract of COVID-19 Patients. Cell Host & Microbe. 27, 883-890.e2 (2020).
5

10

15

20

28. WHO Solidarity Trial Consortium, H. Pan, R. Peto, A.-M. Henao-Restrepo, M.-P. Preziosi,
V. Sathiyamoorthy, Q. Abdool Karim, M. M. Alejandria, C. Hernández García, M.-P.
Kieny, R. Malekzadeh, S. Murthy, K. S. Reddy, M. Roses Periago, P. Abi Hanna, F. Ader,
A. M. Al-Bader, A. Alhasawi, E. Allum, A. Alotaibi, C. A. Alvarez-Moreno, S. Appadoo,
A. Asiri, P. Aukrust, A. Barratt-Due, S. Bellani, M. Branca, H. B. C. Cappel-Porter, N.
Cerrato, T. S. Chow, N. Como, J. Eustace, P. J. García, S. Godbole, E. Gotuzzo, L.
Griskevicius, R. Hamra, M. Hassan, M. Hassany, D. Hutton, I. Irmansyah, L. Jancoriene, J.
Kirwan, S. Kumar, P. Lennon, G. Lopardo, P. Lydon, N. Magrini, T. Maguire, S.
Manevska, O. Manuel, S. McGinty, M. T. Medina, M. L. Mesa Rubio, M. C. MirandaMontoya, J. Nel, E. P. Nunes, M. Perola, A. Portolés, M. R. Rasmin, A. Raza, H. Rees, P.
P. S. Reges, C. A. Rogers, K. Salami, M. I. Salvadori, N. Sinani, J. A. C. Sterne, M.
Stevanovikj, E. Tacconelli, K. A. O. Tikkinen, S. Trelle, H. Zaid, J.-A. Røttingen, S.
Swaminathan, Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial
Results. N Engl J Med (2020), doi:10.1056/NEJMoa2023184.
29. N. Peiffer-Smadja, Y. Yazdanpanah, Nebulised interferon beta-1a for patients with
COVID-19. Lancet Respir Med (2020), doi:10.1016/S2213-2600(20)30523-3.
30. E. Monchatre-Leroy, S. Lesellier, M. Wasniewski, E. Picard-Meyer, C. Richomme, F.
Boué, S. Lacôte, S. Murri, C. Pulido, J. Vulin, F. J. Salguero, M. A. Gouilh, A. Servat, P.
Marianneau, bioRxiv, in press, doi:10.1101/2020.09.24.311977.

25

30

35

31. K. A. Ryan, K. R. Bewley, S. A. Fotheringham, G. S. Slack, P. Brown, Y. Hall, N. I. Wand,
A. C. Marriott, B. E. Cavell, J. A. Tree, L. Allen, M. J. Aram, T. J. Bean, E. Brunt, K. R.
Buttigieg, D. P. Carter, R. Cobb, N. S. Coombes, S. J. Findlay-Wilson, K. J. Godwin, K. E.
Gooch, J. Gouriet, R. Halkerston, D. J. Harris, T. H. Hender, H. E. Humphries, L. Hunter,
C. M. K. Ho, C. L. Kennard, S. Leung, S. Longet, D. Ngabo, K. L. Osman, J. Paterson, E. J.
Penn, S. T. Pullan, E. Rayner, O. Skinner, K. Steeds, I. Taylor, T. Tipton, S. Thomas, C.
Turner, R. J. Watson, N. R. Wiblin, S. Charlton, B. Hallis, J. A. Hiscox, S. Funnell, M. J.
Dennis, C. J. Whittaker, M. G. Catton, J. Druce, F. J. Salguero, M. W. Carroll, Dosedependent response to infection with SARS-CoV-2 in the ferret model and evidence of
protective immunity. Nat Commun. 12, 81 (2021).
32. V. M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D. K. Chu, T. Bleicker, S.
Brünink, J. Schneider, M. L. Schmidt, D. G. Mulders, B. L. Haagmans, B. van der Veer, S.
van den Brink, L. Wijsman, G. Goderski, J.-L. Romette, J. Ellis, M. Zambon, M. Peiris, H.
Goossens, C. Reusken, M. P. Koopmans, C. Drosten, Detection of 2019 novel coronavirus
(2019-nCoV) by real-time RT-PCR. Euro Surveill. 25 (2020), doi:10.2807/15607917.ES.2020.25.3.2000045.

9

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

33. A. Marzi, L. Banadyga, E. Haddock, T. Thomas, K. Shen, E. J. Horne, D. P. Scott, H.
Feldmann, H. Ebihara, A hamster model for Marburg virus infection accurately
recapitulates Marburg hemorrhagic fever. Sci Rep. 6, 39214 (2016).
5

10

34. T. Schountz, C. Campbell, K. Wagner, J. Rovnak, C. Martellaro, B. L. DeBuysscher, H.
Feldmann, J. Prescott, Differential Innate Immune Responses Elicited by Nipah Virus and
Cedar Virus Correlate with Disparate In Vivo Pathogenesis in Hamsters. Viruses. 11
(2019), doi:10.3390/v11030291.
35. M. Zivcec, D. Safronetz, E. Haddock, H. Feldmann, H. Ebihara, Validation of assays to
monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J.
Immunol. Methods. 368, 24–35 (2011).
36. C. Atkins, J. Miao, B. Kalveram, T. Juelich, J. K. Smith, D. Perez, L. Zhang, J. L. B.
Westover, A. J. Van Wettere, B. B. Gowen, Z. Wang, A. N. Freiberg, Natural History and
Pathogenesis of Wild-Type Marburg Virus Infection in STAT2 Knockout Hamsters. J
Infect Dis. 218, S438–S447 (2018).

15

20

25

30

35

40

37. K. Toth, S. R. Lee, B. Ying, J. F. Spencer, A. E. Tollefson, J. E. Sagartz, I.-K. Kong, Z.
Wang, W. S. M. Wold, STAT2 Knockout Syrian Hamsters Support Enhanced Replication
and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon
Response in Viral Control. PLoS Pathog. 11, e1005084 (2015).
38. L. Yang, Y. Han, B. E. Nilsson-Payant, V. Gupta, P. Wang, X. Duan, X. Tang, J. Zhu, Z.
Zhao, F. Jaffré, T. Zhang, T. W. Kim, O. Harschnitz, D. Redmond, S. Houghton, C. Liu, A.
Naji, G. Ciceri, S. Guttikonda, Y. Bram, D.-H. T. Nguyen, M. Cioffi, V. Chandar, D. A.
Hoagland, Y. Huang, J. Xiang, H. Wang, D. Lyden, A. Borczuk, H. J. Chen, L. Studer, F.
C. Pan, D. D. Ho, B. R. tenOever, T. Evans, R. E. Schwartz, S. Chen, A Human Pluripotent
Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in
Human Cells and Organoids. Cell Stem Cell. 27, 125-136.e7 (2020).

Acknowledgments: We thank Meriadeg Ar Gouilh and Astrid Vabret (University Hospital of
Caen, Normandie Université, Caen, France) for granting access to the SARS-CoV-2 UCN1
strain and Daniel Gonzalez-Dunia for proofreading the manuscript. We thank Vanessa Bastid,
Mélanie Badré-Biarnais, Jean-Marc Boucher, Anouck Labadie, Carine Peytavin de Garam,
Jonathan Rieder and Jean-Luc Schereffer for their investment in virological and serological
analyses; Valère Brogat, Sébastien Kempff and Estelle Litaize for animal care and
experimentation (Nancy laboratory for rabies and wildlife, ANSES, Lyssavirus Unit, Malzéville,
France). Funding: this work was funded by a grant from the Agence Nationale de la Recherche
(ANR-20-COV5-0004). Author contributions: R.V., G.F., P.B. and E.M.L. conceptualized and
designed experiments. P.B., M.W., E.P.M., A.S., T.F., C.F.L., A.C., S.L., F.B., N.C., B.G., C.T.,
F.J.S., E.M.L. and R.V. performed experiments. R.V., P.B., F.J.S., G.F. and E.M.L analysed
data. R.V., and P.B. wrote the paper. R.V. acquired funding. Competing interests: Authors
declare no competing interests. Data and materials availability: All data is available in the
main text or the supplementary materials.

10

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Supplementary Materials:
Materials and Methods
Figures S1-S9
Tables S1
5

References (30-38)

11

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

5

Fig. 1. Impact of type I IFN-α treatment on SARS-CoV-2-induced weight loss and viral
titers. (A) Overview study design. (B) Percentage of body weight change with weight measured
day 1 pre-infection before the IFN-pre treatment set as the reference weight (6 animals per
group). (C). Viral genomic RNA in oropharyngeal swabs (6 animals per group). The dotted line
indicates limit of detection. (D and E) Lungs viral titers determined by RT-qPCR targeting viral
sgRNA relative to the housekeeping genes RPL18 and RPS6KB1 (D) and by TCID50 (E). D2:
day 2 post infection; D5: day 5 post infection. Results are expressed as means ± SEM.

12

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

5

Fig. 2. Histopathological analysis of the impact of type I IFN-α treatment. (A)
Representative pictures were selected to display the pathology from haematoxylin and eosin
(H&E) stained lung section from animals at day 5 post infection. (B) Severity of lung pathology
based on lesional scores evaluated from haematoxylin and eosin (H&E) stained lung section. (C)
Quantification of percent lung area positive for viral RNA in lung sections stained with
RNAScope in situ hybridization (ISH). (D) Quantification of percent lung area positive for Mx1
protein detected by immunohistochemistry (IHC). D2: day 2 post infection; D5: day 5 post
infection; D15: day 15 post infection. Results are expressed as means ± SEM.
13

bioRxiv preprint doi: https://doi.org/10.1101/2021.02.09.430458; this version posted February 9, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

5

Fig. 3. Impact of type I IFN-α treatment on the immune response to SARS-CoV-2. (A) Lung
transcripts levels of Mx2, ISG15, IFN-γ, CXCL10, IL-6 and IL-10 relative to the housekeeping
genes RPL18 and RPS6KB1 determined by RT-qPCR. (B) Lung protein levels for CXCL10, IL6, IL-10 and IL-1β protein levels determined by ELISA or a multiplex assay. (C) Plasmatic
protein levels for CCL2 and TNF-α determined by a multiplex assay. D2: day 2 post infection;
D5: day 5 post infection; D15: day 15 post infection. Results are expressed as means ± SEM.
14

